PDB62 Profile of Patients Treated with Insulin Lispro 200 U/ML in the Real World: Profile IL-200 Study

Abstract

There are limited data on the use of insulin lispro 200 U/mL (IL200) in clinical practice in Spain. This real world study (PROFILE-IL200) describes the clinical/demographic characteristics, and treatment, of patients who initiate IL200 therapy. This retrospective observational study based on the IQVIA medical records database in Spain included adult (≥18 years) patients with type 1 (T1D) and type 2 (T2D) diabetes who initiated IL200 between 1st June 2015 and 31st December 2019. The patients’ demographic and clinical characteristics on the index date (date of IL200 initiation), medical history, initial dose of IL200, previous and concomitant antidiabetic therapy were analysed descriptively by diabetes type. Total daily insulin dose (U) before index was calculated as the mean of basal and rapid insulin prescriptions available in the 90-day pre-index period, and at index with prescriptions in the following 60 days. Main characteristics for the T1D/T2D groups (N=65/167) were, respectively: male, 63.1%/55.7%; mean (standard deviation [SD]) age, 46.5 (15.5)/62.6 (12.8) years; time since diagnosis, 6.6 (4.2)/7.9 (2.9) years; body mass index, 30.9 (5.8)/33.1 (5.5) kg/m2; HbA1c 8.3 (2.1)/8.8 (1.8)%; diabetes-associated comorbidity present, 55.4%/92.8%. Fourteen patients were new diagnoses. Among T1D/T2D with a prior diagnosis (N=54/164), 96.3%/90.2% had previous insulin, (rapid insulin in 81.5%/62.2%); 13.0% (n=7)/97.6% previous non-insulin antidiabetic therapy. The mean (SD) insulin dose pre-index for T1D/T2D was 98 (73.9)/95.2 (59.8) U/day. IL200 was initiated at a mean (SD) dose of 56.3 (43.8) and 51.5 (34.3) U/day for T1D/T2D, with basal insulin in 86.2%/83.2%. IL200 was first prescribed by an endocrinologist (48.7%), and by the general practitioner in 46.6% of patients. This is the first study that describes the profile of patients treated with IL200 in clinical practice in Spain. These T1D and T2D patients presented a high body mass index, associated comorbidities and received high doses of insulin at IL200 initiation.